At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 366 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration·interventional·Posted Apr 23, 2007·Updated Nov 23, 2018
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Rhabdomyosarcoma and 9 related conditions. Completed, enrolled 366 participants across 20 sites.
Detailed Summary
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's, Sarcoma, Alveolar Soft Part, Chordoma, Epithelioid Sarcoma, Giant Cell Tumor of Bone, Hemangiopericytoma, Gastrointestinal Stromal Tumor (GIST)
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartMay 2007
Primary CompletionDec 2016
Study CompletionMay 2017
TodayJul 2026
First PostedApr 23, 2007
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2016
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 19.2 years ago
Interventions
Dasatinibdrug
oral agent, continuous dosing, Cycles = 28 days